Veterinary Medicines

FATROXIMIN, putojančios gimdos ovulės

Authorised
  • Rifaximin
Download as PDF

Product identification

Medicine name:
FATROXIMIN, putojančios gimdos ovulės
Active substance:
  • Rifaximin
Target species:
  • Cattle (cow)
  • Buffalo (female)
  • Horse (mare)
  • Pig (sow)
  • Sheep (ewe)
  • Goat (adult female)
Route of administration:
  • Intrauterine use

Product details

Active substance and strength:
  • Rifaximin
    300.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Intrauterine tablet
Withdrawal period by route of administration:
  • Intrauterine use
    • Cattle (cow)
      • Meat and offal, milk
        0
        day
    • Buffalo (female)
      • Meat and offal, milk
        0
        day
    • Horse (mare)
      • Meat and offal, milk
        0
        day
    • Pig (sow)
      • Meat and offal
        0
        day
    • Sheep (ewe)
      • Meat and offal, milk
        0
        day
    • Goat (adult female)
      • Meat and offal, milk
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG51AA06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Available in:
  • Lithuania
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis reviewed according to Acquis communautaire
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • State Food And Veterinary Service
Authorisation number:
  • LT/2/01/1282/001-002
Date of authorisation status change:

Documents

RV1282.pdf

Lithuanian (PDF)
Published on: 8/06/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."